The abstract is read at the publisher; the summary is JClub's.
TumorDressed CCR7+ migratory dendritic cells generated from universal MHC-deficient hiPSCs prime anti-tumor T cell cytotoxicity in vitro and in vivo, including against primary hematologic and solid tumors.
- Why it matters: Autologous DC vaccines are limited by the quantity and antigen presentation quality of patient-derived cells, and by the diversity of antigens they can display.
- What they did: Universal MHC-deficient hiPSCs were differentiated into CCR7+ migratory DCs and then dressed with the full repertoire of MHC–antigen complexes from tumor cell membranes; T cell activation and cytotoxicity were tested with CD80/86 and PD-L1/2 deletions.
- The result: TumorDressed DCs activate T cells against tumor antigens, with reduced function after CD80/86 deletion and enhanced priming after PD-L1/2 loss, supporting a scalable off-the-shelf vaccine platform.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.